acquired
Stage
1
Investors
About
X-Cell Medical developed integrated drug-eluting stents (DES) aimed at treating restenosis and other cardiovascular conditions. Its lead program applied 17-β-estradiol on DES to enhance endothelial growth and help reduce sub-acute thrombosis.
Explore X-Cell Medical's full profile on Brouky
Funding rounds, investor list, and risk signals — unlock with a subscription.